Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Monopar Therapeutics changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 204.5K | 208.0K | +3.55K (+1.7%) |
| Value | $519.8K | $470.6K | −$49.2K (−9.5%) |
New holders (2)
Institutions that held Monopar Therapeutics at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 10 | $0 | 0.00% |
| Captrust Financial Advisors | 170 | $0 | 0.00% |
Sold out (2)
Institutions that held Monopar Therapeutics at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| FinTrust Capital Advisors, LLC | 500 | $1.00K |
| Glassman Wealth Services | 1 | $0 |